Gilead, Abbott should benefit from first mover HCV advantage, says Wells Fargo

After speaking with executives at two managed care companies, Wells Fargo expects Gilead and Abbott to benefit meaningfully from their first mover advantage in the HCV market. The firm believes that Abbott may be on more of equal footing to Gilead, at least among payers.

View Comments (1)